308 related articles for article (PubMed ID: 9426083)
1. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency.
Palmqvist M; Persson G; Lazer L; Rosenborg J; Larsson P; Lötvall J
Eur Respir J; 1997 Nov; 10(11):2484-9. PubMed ID: 9426083
[TBL] [Abstract][Full Text] [Related]
2. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
van der Woude HJ; Winter TH; Aalbers R
Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
[TBL] [Abstract][Full Text] [Related]
3. Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline.
Richter K; Janicki S; Jörres RA; Magnussen H
Eur Respir J; 2002 May; 19(5):865-71. PubMed ID: 12030726
[TBL] [Abstract][Full Text] [Related]
4. Relief of dyspnoea by beta2-agonists after methacholine-induced bronchoconstriction.
van der Woude HJ; Postma DS; Politiek MJ; Winter TH; Aalbers R
Respir Med; 2004 Sep; 98(9):816-20. PubMed ID: 15338791
[TBL] [Abstract][Full Text] [Related]
5. Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma.
Pohunek P; Matulka M; Rybnícek O; Kopriva F; Honomichlová H; Svobodová T
Pediatr Allergy Immunol; 2004 Feb; 15(1):32-9. PubMed ID: 14998380
[TBL] [Abstract][Full Text] [Related]
6. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol.
Lipworth BJ; Aziz I
J Allergy Clin Immunol; 1999 Jan; 103(1 Pt 1):88-92. PubMed ID: 9893190
[TBL] [Abstract][Full Text] [Related]
7. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
[TBL] [Abstract][Full Text] [Related]
8. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction.
Politiek MJ; Boorsma M; Aalbers R
Eur Respir J; 1999 May; 13(5):988-92. PubMed ID: 10414394
[TBL] [Abstract][Full Text] [Related]
9. Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study.
Brambilla C; Le Gros V; Bourdeix I;
Clin Ther; 2003 Jul; 25(7):2022-36. PubMed ID: 12946548
[TBL] [Abstract][Full Text] [Related]
10. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers.
Palmqvist M; Arvidsson P; Beckman O; Peterson S; Lötvall J
Pulm Pharmacol Ther; 2001; 14(1):29-34. PubMed ID: 11162416
[TBL] [Abstract][Full Text] [Related]
11. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action.
van Noord JA; Smeets JJ; Raaijmakers JA; Bommer AM; Maesen FP
Eur Respir J; 1996 Aug; 9(8):1684-8. PubMed ID: 8866595
[TBL] [Abstract][Full Text] [Related]
12. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
Aziz I; Hall IP; McFarlane LC; Lipworth BJ
J Allergy Clin Immunol; 1998 Mar; 101(3):337-41. PubMed ID: 9525449
[TBL] [Abstract][Full Text] [Related]
13. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study.
Cazzola M; Matera MG; Santangelo G; Vinciguerra A; Rossi F; D'Amato G
Respir Med; 1995 May; 89(5):357-62. PubMed ID: 7638371
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.
Bjermer L; Rosenborg J; Bengtsson T; Lötvall J
Ther Adv Respir Dis; 2013 Oct; 7(5):264-71. PubMed ID: 23907810
[TBL] [Abstract][Full Text] [Related]
15. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action.
Celik G; Kayacan O; Beder S; Durmaz G
Respiration; 1999; 66(5):434-9. PubMed ID: 10516540
[TBL] [Abstract][Full Text] [Related]
16. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects.
Guhan AR; Cooper S; Oborne J; Lewis S; Bennett J; Tattersfield AE
Thorax; 2000 Aug; 55(8):650-6. PubMed ID: 10899240
[TBL] [Abstract][Full Text] [Related]
17. Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism.
Lipworth BJ; Dempsey OJ; Aziz I
Chest; 2000 Aug; 118(2):321-8. PubMed ID: 10936119
[TBL] [Abstract][Full Text] [Related]
18. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler.
Bensch G; Lapidus RJ; Levine BE; Lumry W; Yegen U; Kiselev P; Della Cioppa G
Ann Allergy Asthma Immunol; 2001 Jan; 86(1):19-27. PubMed ID: 11206232
[TBL] [Abstract][Full Text] [Related]
19. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD.
Cazzola M; Di Perna F; Noschese P; Vinciguerra A; Calderaro F; Girbino G; Matera MG
Eur Respir J; 1998 Jun; 11(6):1337-41. PubMed ID: 9657576
[TBL] [Abstract][Full Text] [Related]
20. [Changes in specific airway resistance after powder inhalation of formoterol or salmeterol in moderate bronchial asthma].
Sill V; Bartuschka B; Villiger B; Ortland C; Domej W
Pneumologie; 1999 Jan; 53(1):4-9. PubMed ID: 10091511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
